User:Ritsner

Michael S. Ritsner, MD, PhD Director Department of Psychiatry of the Sha'ar Menashe Mental Health Center, ISRAEL

Contact Details: S. Michael Ritsner, MD, PhD. Dept. Psychiatry, Sha'ar Menashe Mental Health Center; Mobile Post Hefer 38814, ISRAEL Phone: +972 4 6278750 (w); Fax: +972 4 6278045; Email: ritsner@sm.health.gov.il and ritsnerm@gmail.com Web: http://md.technion.ac.il/lecturers/lecturer_desc.asp?lecturerID=393

Dr. S. Michael Ritsner, MD, PhD is a physician and scientist who spent his career of over 35 years caring for patients and studying the nature and treatment of mental illness. He is A/Professor in the Department of Psychiatry at the Rappaport Faculty of Medicine, Technion - Israel Institute of Technology (Haifa), where he also serves as head of the Cognitive & Psychobiology Research Laboratory. He is also a certified psychiatrist who continues to see patients. After receiving his medical degree from the Khabarovsk State Medical University, and received his PhD in Psychiatry from the Siberian State Medical University in 1975 (Tomsk, Russia), Dr. Ritsner gained clinical practice as a neurologist and clinical psychiatrist. In 1981 he joined the Siberian State Research Center at the Russian Academy of Medical Sciences (Tomsk) as a Head of the Psychiatric Genetics Department. In 1990 he immigrated to Israel where he chaired a Psychiatry Department and the Research Unit at Talbieh Mental Health Center (Jerusalem). Since 1998 Dr. Ritsner directs the Acute Department of the Sha'ar Menashe MHC affiliated to the Rappaport Faculty of Medicine (Technion). Dr. Ritsner served as Associate Editor, An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation (The Netherlands); Board Member, American Journal of Neuroprotection and Neuroregeneration (USA); CNS & Neurological Disorders-Drug Targets (Italy); member of the Scientific Committee, International Society for the Study of Neuroprotection and Neuroplasticity (Romania). Dr. Ritsner is internationally renowned for his research in schizophrenia spectrum disorders (molecular genetics, neurosteroids, novel neuroprotective treatments), and has long advocated the view that quality of life impairments is a core syndrome of schizophrenia and related disorders. He also directs the Stanley Foundation (USA)-funded a multi-site study, which was aimed to test novel neuroprotective agents. Dr. Ritsner is the author of over 140 peer-reviewed scientific articles and reviews, more than 20 book chapters as well as 12 edited volumes and two monographs in neuropsychiatry. He has given more than 200 presentations including as invited speaker at scientific conferences and medical education events. Last monograph is yet another milestone toward achieving his goals of providing a comprehensive up-to-date state-of-the-art overview of the literature that addresses the challenges facing clinical and biological psychiatry. This series follows 12 volumes: 1. Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders. New Perspectives on Research and Treatment. Ritsner, Michael S.; Awad, A. George (Eds.), Springer, Dordrecht. The Netherlands, 2007, 388 p. 2. Neuroactive Steroids in Brain Functions, and Mental Health. Novel Strategies for Research and Treatment. Ritsner, Michael S.; Weizman A. (Eds.), Springer Science + Business Media, B.V., 2008. 559 p. 3. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes, and Genes. Volumes I–IV. Ritsner, Michael S. (Ed.), Springer Science + Business Media, B.V., 2009. • Volume I: Neuropsychological Endophenotypes and Biomarkers. 231 pp. • Volume II: Neuroanatomical and Neuroimaging Endophenotypes and Biomarkers. 244 pp. • Volume III: Metabolic and Peripheral Biomarkers. 231 pp. • Volume IV: Molecular Genetic and Genomic Markers. 232 pp. 4. Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Ritsner, Michael S. (Ed.), Springer Science + Business Media, B.V. 2010. 663 p. 5. Handbook of Schizophrenia Spectrum Disorders. Volumes I–III. Ritsner, Michael S. (Ed.), Springer Science + Business Media, B.V. 2011. • Volume I: Conceptual Issues and Neurobiological Advances. 494 pp. • Volume II: Phenotypic and Endophenotypic Presentations. 526 pp. • Volume III: Therapeutic Approaches, Comorbidity, and Outcomes. 461 pp. 6. Polypharmacy in Psychiatric Practice. Volumes I–II. Ritsner, Michael S. (Ed.), Springer Science + Business Media, B.V. 2013.